Top

Journal of Hematology & Oncology

Published in:

Open Access 01-12-2019 | Correction

Correction to: Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells

Authors: Kai Zhao, Yuxin Zhou, Chen Qiao, Ting Ni, Zhiyu Li, Xiaotang Wang, Qinglong Guo, Na Lu, Libin Wei

Published in: Journal of Hematology & Oncology | Issue 1/2019

Excerpt

Correction to: J Hematol Oncol …

Zhao K, Zhou Y, Qiao C, Ni T, Li Z, Wang X, et al. Oroxylin a promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells. J Hematol Oncol. 2015;8:41 https://doi.org/10.1186/s13045-015-0137-1.CrossRef

Title: Correction to: Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells
Authors: Kai Zhao
Yuxin Zhou
Chen Qiao
Ting Ni
Zhiyu Li
Xiaotang Wang
Qinglong Guo
Na Lu
Libin Wei
Publication date: 01-12-2019
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2019
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-019-0792-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2019

Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition

Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma

Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy

Correction to: High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer